Your browser doesn't support javascript.
loading
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System.
Sparano, Francesco; Giesinger, Johannes M; Gaidano, Gianluca; Anota, Amelie; Cavo, Michele; Brini, Alberto; Voso, Maria Teresa; Venditti, Adriano; Perrone, Francesco; Di Maio, Massimo; Luppi, Mario; Baron, Frederic; Platzbecker, Uwe; Fazi, Paola; Vignetti, Marco; Efficace, Fabio.
Afiliación
  • Sparano F; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
  • Giesinger JM; University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
  • Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy.
  • Anota A; Biostatistics Unit, Direction of Clinical Research and Innovation, Human and Social Sciences Department, and French National Platform Quality of Life and Cancer, Centre Léon Bérard, Lyon, France.
  • Cavo M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Università di Bologna, Bologna, Italy.
  • Brini A; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
  • Voso MT; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Venditti A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Perrone F; Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy.
  • Di Maio M; Department of Oncology, Oncology Unit, University of Torino, Ordine Mauriziano Hospital, Torino, Italy.
  • Luppi M; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Modena, Italy.
  • Baron F; Department of Hematology, University and CHU of Liège, Liège, Belgium.
  • Platzbecker U; Clinic and Policlinic of Hematology and Cellular Therapy, Oncology and Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
  • Fazi P; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
  • Vignetti M; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
  • Efficace F; Data Center and Health Outcomes Research Unit, Italian Group for Adult Haematologic Diseases (GIMEMA), Rome, Italy.
JCO Oncol Pract ; 20(3): 438-447, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38207239
ABSTRACT

PURPOSE:

We investigated the association of financial toxicity (FT) with the health-related quality of life (HRQoL) profile of patients with hematologic malignancies treated in a universal health care system.

METHODS:

We did a secondary analysis of six multicenter studies enrolling patients with hematologic malignancies. FT was evaluated using the financial difficulties item of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Multivariable linear regression models were used to assess the mean differences in HRQoL scores between patients with or without FT, while adjusting for key potential confounding factors. We also examined the prevalence of clinically important problems and symptoms by the experience of FT, using established thresholds for the EORTC QLQ-C30. Multivariable binary logistic regression analysis was performed to explore the risk factors associated with FT.

RESULTS:

Overall, 1,847 patients were analyzed, of whom 441 (23.9%) reported FT. We observed statistically and clinically relevant worse scores for patients with FT compared with those without FT for all the EORTC QLQ-C30 scales. The three largest clinically relevant mean differences between patients with and without FT were observed in pain (∆ = 19.6 [95% CI, 15.7 to 23.5]; P < .001), social functioning (∆ = -18.9 [95% CI, -22.5 to -15.2]; P < .001), and role functioning (Δ = -17.7 [95% CI, -22.1 to -13.3]; P < .001). Patients with FT tended to report a higher prevalence of clinically important problems and symptoms across all EORTC QLQ-C30 scales. In the univariable and multivariable analyses, the presence of FT was associated with the presence of comorbidities, an Eastern Cooperative Oncology Group performance status ≥1, and not receiving a salary.

CONCLUSION:

Patients with hematologic malignancies treated in the setting of a universal health care system who experience FT have a worse HRQoL profile compared with those without FT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Hematológicas Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JCO Oncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Hematológicas Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: JCO Oncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Italia